The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Basal-luminal subtyping of localized high-risk prostate cancer and benefit of adding docetaxel to definitive radiotherapy with androgen suppression in the NRG Oncology/RTOG 0521 phase III trial.
 
Ryan Phillips
(OPTIONAL) Uncompensated Relationships - Veracyte
 
James A. Proudfoot
Employment - Veracyte
Stock and Other Ownership Interests - Veracyte
 
Elai Davicioni
Employment - Veracyte
Leadership - Veracyte
Stock and Other Ownership Interests - Veracyte
Patents, Royalties, Other Intellectual Property - Veracyte
 
Yang Liu
Employment - Veracyte
Stock and Other Ownership Interests - Veracyte
 
Daniel Eidelberg Spratt
Honoraria - Varian Medical Systems
Consulting or Advisory Role - AstraZeneca; Bayer; Blue Earth Diagnostics; Boston Scientific; Janssen Oncology; Myovant Sciences; Pfizer; Varian Medical Systems
Research Funding - Janssen (Inst)
 
Felix Y Feng
Stock and Other Ownership Interests - Artera; Bluestar Genomics; Serimmune
Consulting or Advisory Role - Artera; Astellas Pharma; Bayer; BlueStar Genomics; Bristol Myers Squibb; Bristol Myers Squibb (BMS); Exact Sciences; Foundation Medicine; Janssen Biotech; Myovant Sciences; Novartis; POINT Biopharma; Roivant; SerImmune; Tempus; Varian Medical Systems
Research Funding - Zenith Epigenetics
 
Jeff Simko
No Relationships to Disclose
 
Robert Benjamin Den
Employment - Alpha TAU; Alpha TAU
 
Alan Pollack
Research Funding - Varian Medical Systems; Veracyte
 
Seth A. Rosenthal
No Relationships to Disclose
 
A. Oliver Sartor
Stock and Other Ownership Interests - Abbvie; Cardinal Health; Clarity Pharmaceuticals; Clovis Oncology; GlaxoSmithKline; Lilly; Noria Therapeutics; PSMA Therapeutics; United Health Group
Consulting or Advisory Role - Advanced Accelerator Applications; ARTbio; Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Clarity Pharmaceuticals; Clovis Oncology; Constellation Pharmaceuticals; Dendreon; EMD Serono; Fusion Pharmaceuticals; Hengrui Therapeutics; Isotopen Technologien; Janssen; Merck; Morphimmune; Myovant Sciences; Myriad Genetics; Noria Therapeutics; Northstar; Novartis; Noxopharm; Pfizer; Point Biopharma; Progenics; Sanofi; Telix Pharmaceuticals; TEmpus; TeneoBio; Tessa Therapeutics; Theragnostics
Research Funding - Advanced Accelerator Applications (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Endocyte (Inst); InVitae (Inst); Janssen; Lantheus Medical Imaging (Inst); Merck (Inst); Progenics; Sanofi (Inst); SOTIO
Patents, Royalties, Other Intellectual Property - Koochekpour, Sartor AO, inventors. Saposin C and receptors as targets for treatment of benign and malignant disorders. US patent awarded January 23, 2007 (patent no. 7,166,691).
Expert Testimony - Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Johnson & Johnson; Progenics; Sanofi
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Genentech/Roche; Janssen Biotech; Lilly; Pfizer; POINT Biopharma; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Pfizer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination
 
Gerhardt Attard
Honoraria - Astellas Pharma; Janssen; Janssen (I)
Consulting or Advisory Role - Abbott Laboratories; Astellas Pharma; AstraZeneca; Bayer; ESSA; Ferring; Janssen-Cilag; Medivation; Millennium; Novartis; Pfizer; Ventana Medical Systems; Veridex
Speakers' Bureau - Astellas Pharma; AstraZeneca; Ferring; Ipsen; Janssen; Sanofi; Takeda; Ventana Medical Systems
Research Funding - Arno Therapeutics (Inst); Innocrin Pharma (Inst); Janssen (Inst)
Patents, Royalties, Other Intellectual Property - I am on The ICR rewards to inventors list of abiraterone acetate.
Travel, Accommodations, Expenses - Abbott Laboratories; Astellas Pharma; Astellas Pharma (I); Bayer; ESSA; Ferring; Janssen; Janssen (I); Medivation; Pfizer; Ventana Medical Systems
Other Relationship - Institute of Cancer Research
 
Samir Patel
Consulting or Advisory Role - Mevion Medical Systems
 
Michael Wayne Straza
No Relationships to Disclose
 
Jason A. Efstathiou
Consulting or Advisory Role - AstraZeneca; Bayer; Blue Earth Diagnostics; Blue Earth Diagnostics; Boston Scientific; Genentech; Gilead Sciences; Janssen; Lantheus Medical Imaging; Merck; Myovant Sciences; Pfizer; Progenics
 
Amit Shah
No Relationships to Disclose
 
Joseph P. Rodgers
No Relationships to Disclose
 
Howard M. Sandler
Consulting or Advisory Role - Janssen
Other Relationship - Caribou Publishing
 
Phuoc T. Tran
Honoraria - Reflexion Medical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Health; Bayer Health; Dendreon; GenomeDx; Janssen; Myovant Sciences; Noxopharm; Reflexion Medical; Reflexion Medical; Regeneron
Research Funding - Astellas Pharma (Inst); Bayer Health (Inst); Reflexion Medical (Inst)
Patents, Royalties, Other Intellectual Property - Compounds and Methods of Use in Ablative Radiotherapy. Patent filed 3/9/2012. PCT/US2012/028475. PCT/WO/2012/122471.
Travel, Accommodations, Expenses - Reflexion Medical